Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 79, Issue 1, 2008, Pages 97-102

  Kawamori, Ryuzo ^a   Eliaschewitz, Freddy G ^b   Takayama, Hideichi ^c   Hayashida, Cesar Y ^d  

^a JUNTENDO UNIVERSITY   (Japan)

^b HOSPITAL HELIÓPOLIS   (Brazil)

^c Sanofi aventis KK ^*  (Japan)

^d Sociedade Beneficente de Cotia Hospital   (Brazil)

Author keywords

C peptide; Glimepiride; HbA1c; Insulin glargine

Indexed keywords

C PEPTIDE; CARBOHYDRATE; CHOLESTEROL; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JAPAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INSULIN; JAPAN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 37549044225     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.08.007     Document Type: Article

References (31)

1. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 DM (UKPDS 33). Lancet 352 (1998) 837-853
2. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R., and Turner R.C. Sulfonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet. Med. 15 (1998) 297-303
3. UK Prospective DM Study Group. U.K. Prospective DM Study 16, overview of 6 years' therapy of type II DM: a progressive disease. DM 44 (1995) 1249-1258
4. Turner R.C., Cull C.A., Frighi V., Holman R.R., and The UK Prospective DM Study Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 DM mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2012
5. Riddle M., Hart J., Bingham P., Garrison C., and McDaniel P. Combined therapy for obese type 2 DM: suppertime mixed insulin with daily sulfonylurea. Am. J. Med. Sci. 303 (1992) 151-156
6. Shank M.L., Del Prato S., and DeFronzo R.A. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. DM 44 (1995) 165-172
7. Wright A., Burden A.C.F., Paisey R.B., Cull C.A., Holman R.R., and For the UK Prospective DM Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 DM in the U.K. Prospective DM Study. DM Care 25 (2002) 330-336
8. Fritsche A., Schweitzer M.A., Haring H.U., and 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 DM. A randomized, controlled trial. Ann. Intern. Med. 138 (2003) 952-959
9. Standl E., Maxeiner S., Raptis S., Karimi-Anderesi Z., Schweitzer M.A., and The HOE901/4009 Study Group. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. DM Care 28 (2005) 419-420
10. Standl E., Maxeiner S., and Raptis S. Once daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm. Metab. Res. 38 (2006) 172-177
11. Rosskamp R.H., and Park G. Long-acting insulin analogs. DM Care 22 (1999) B109-B113
12. Heinemann L., Linkeschova R., Rave K., Hompesch B., Sedlak M., and Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. DM Care 23 (2000) 644-649
13. Binder C., Lauritzen T., Faber O., and Pramming S. Insulin pharmacokinetics. DM Care 7 (1984) 188-199
14. Yki-Järvinen H., Dressler A., Ziemen M., and The HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 DM. DM Care 23 (2000) 1130-1136
15. Goldberg R.B., Holvey S.M., Schneider J., and The Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. DM Care 19 (1996) 849-856
16. Rosenstock J., Samols E., Muchmore D.B., Schneider J., and The Glimepiride Study Group. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. DM Care 19 (1996) 1194-1199
17. Schade D.S., Jovanovic L., and Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 DM mellitus for who diet therapy is unsuccessful. J. Clin. Pharmacol. 38 (1998) 636-641
18. Muller G., and Wied S. The sulfonylurea drug, glimepiride, stimulate glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. DM 42 (1993) 1852-1867
19. Geisen K. Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung 38 (1988) 1120-1130
20. Muller G., Satoh Y., and Geisen K. Extrapancreatic effects of sulfonylureas: a comparison between glimepiride and conventional sulfonylureas. DM Res. Clin. Pract. 28 (1995) S115-S137
21. Sone H., Yoshimura Y., Ito H., Ohashi Y., Yamada N., and Japan DM Complications Study Group. Energy intake and obesity in Japanese patients with type 2 DM. Lancet 363 (2004) 248-249
22. Kosaka K., Kuzuya T., Hagura R., and Yoshinaga H. Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent DM mellitus: the usefulness of decreased early insulin response as a predictor of non-insulin-dependent DM mellitus. Diabet. Med. 13 (1996) S109-S119
23. Ministry of Health, Labour and Welfare, Japan National Nutrition Survey, 2001.
24. Riddle M.C., Rosenstock J., and Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. DM Care 26 (2003) 3080-3086
25. Davies M., Storms F., Shutler S., Bianchi-Biscay M., and Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 DM. DM Care 28 (2005) 1282-1288
26. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 DM (UKPDS 35). BMJ 321 (2000) 405-412
27. Korytkowski M., Thomas A., Reid L., Tedesco M.B., Gooding W.E., and Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 DM. DM Care 25 (2002) 1607-1611
28. Iwamoto Y., and Yamada N. Latest clinical information from diabetic mellitus specialists, Tokyo. Chugai-Igaku (1977) 153
29. Clifton P. The science behind weight loss diets: a brief review. Aust. Fam. Physician 35 8 (August 2006)
30. Ferreira S.R., Lerario D.D., Gimenio S.G., Sanudo A., and Franco L.J. Obesity and central adiposity in Japanese immigrants: role of the western dietary pattern. J. Epidemiol. 12 (2002) 431-438
31. Moore H., Summerbell C., Hooper L., Cruickshank K., Vyas A., Johnstone P., et al. Dietary Advice for Treatment of Type 2 Diabetes Mellitus in Adults, The Cochrane Collaboration (2004), John Wiley & Sons, Ltd.